Implied Podcast

Figma, the design powerhouse that nearly merged with Adobe for $20 billion, is now trading around $36—a staggering 75% drop from its $142 post-IPO high. But don't let the price tag fool you. While the stock looks like a "broken IPO," the business is hitting massive milestones, including crossing the $1 billion annual revenue run rate with 38% growth.

In this episode of Implied, we peel back the curtain on why a $1.1 billion paper loss is masking a cash-rich company with $1.5 billion on the sidelines. We explore how Figma’s acquisition of the AI startup Weavy is turning the tables on Adobe and why a 131% net dollar retention rate makes this one of the stickiest products in tech history. Is this a valuation trap at 18x sales, or a rare chance to buy a generational leader at a deep discount? Tune in for the full breakdown of Figma’s wild 2026 trajectory.

Abercrombie & Fitch just saw an 18% hole blown in its stock chart, despite reporting record holiday demand. Why the panic? Wall Street is fixating on a new $90 million tariff bill and rising capital expenses, ignoring the brand’s massive turnaround success. In this episode, we break down why "good" isn't good enough for this market anymore and analyze the setup: is this a warning signal for retail margins, or a massive "sell-the-news" overreaction that created a buying opportunity?

Coty shares are seeing ghosts, trading near 52-week lows at $3.06 after being practically cut in half over the last year. Despite a massive $750 million cash injection from selling its Wella stake, Wall Street is terrified by a sudden CEO shakeup and a wider crisis hitting rival Estée Lauder. In this episode, we break down why the market hates the uncertainty—and why they might be missing the massive debt paydown happening behind the scenes. Is this a "falling knife" or a cleaner company trading at rock-bottom multiples? Tune in to find out if this is the end of the line or the ultimate value play.

American International Group just surrendered months of gains, shedding nearly 10% in a bloodbath week after a surprise "reserve strengthening" announcement. Investors are fleeing as fears mount that the insurer’s underwriting models are fundamentally broken and "structural damage" has been done. In this episode of Implied, we break down the critical "Combined Ratio" miss, why the market is having 2008 flashbacks, and the risk of "cockroach theory." Is this a rare chance to buy a blue-chip at book value, or is the bleeding just getting started? Dive in to find out why you shouldn't catch this falling knife just yet.

Regencell Bioscience (RGC) just went from a massive 60% rally to a sudden 20% plunge in less than 24 hours—and there is absolutely zero news to explain it. Despite having a market cap floating around $10 billion, the company has generated effectively no revenue and is trading at a staggering 5,000x book value. In this episode, we break down the dangerous mechanics behind this "roller coaster," the shadow of a DOJ probe, and why this stock is behaving less like an investment and more like a "lottery ticket in a burning building."

SiTime just erased $1 billion in market value in a single session, falling over 10% despite being the heartbeat of modern AI infrastructure. The stock has been a rocket ship—up 56% in the last year—but today it sliced through key technical levels as investors finally questioned its astronomical valuation. Is this a disastrous breakdown, or a rare chance to buy the "Endura" defense play at a discount? In this episode, we analyze whether this massive selloff is just a shakeout of the "tourists" or a warning not to catch a falling knife.

Just 24 hours ago, D-Wave Quantum was flying high on CES 2026 news—but today, the stock crashed nearly 10%. Why? A top executive just unloaded $24 million worth of shares right into the rally. In this episode of Implied, we break down whether this massive insider sale signals a lack of confidence or just a smart cash-out. With an $11 billion valuation on just $3.74 million in quarterly revenue, is the quantum bubble bursting, or will upcoming government contracts save the day? Tune in to find out why you might want to wait before buying this dip.

Axia Energia (formerly Eletrobras) is getting hammered, shedding nearly 10% as its massive rebrand hits a wall. The trigger? A controversial new deal for a green hydrogen plant that investors see as pure cash burn rather than innovation. In this episode, we break down why the market is aggressively rejecting Axia’s pivot from boring utility dividends to high-stakes tech, and whether this selloff is a disastrous "false start"… or a rare chance to buy a future energy giant at a discount.

Nike just face-planted with a massive 10% drop, despite technically beating earnings estimates. Why the bloodbath? The "turnaround" just hit a reality check: crushing tariffs have destroyed margins, and sales in China are in freefall. In this episode of Implied, we look past the headline numbers to explain why CEO Elliott Hill’s "middle innings" narrative isn't sticking. Is the sales jump in North America a sign of life, or is this stock a "falling knife" that you shouldn't touch yet? Tune in for the full breakdown.

Insmed’s 200% rally just hit a brutal wall. The stock crashed 17% after its star drug, Brinsupri, failed a key Phase 2 study—shattering the thesis that it could be a "Swiss Army Knife" for inflammation. Even a surprise acquisition announcement couldn't distract Wall Street from the flop. In this episode, we break down the failed "misdirection" play and analyze the wreckage: Is this a disastrous signal for the rest of the pipeline, or just an overreaction to "spilled gravy" while the core billion-dollar business remains safe?